Brain tumor.
Conditions
Interventions
Intervention 1: Intervention group: Patients in the TXA group will receive tranexamic acid at a dose of 10 mg per kilogram of body weight intravenously before surgery, and then a dose of 5.0 to 2 mg p
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients (=18 years) scheduled for elective craniotomy for brain tumor removal Providing written consent
Exclusion criteria
Exclusion criteria: Patients with known allergies to TXA Patients with a history of thromboembolic disorders Patients currently being treated with anticoagulants Patients with CKD because this drug is predominantly renally metabolized
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of bleeding. Timepoint: Measuring the amount of bleeding during and immediately after the operation. Method of measurement: The amount of bleeding during surgery will be measured using the estimated blood volume in the surgical field and the volume of drainage after the surgery. Each 30*30cm gauze is approximately equivalent to 100 to 130cc of blood loss. Due to the estimated nature of visual methods for estimating blood loss, the lost blood will also be assessed through laboratory tests and monitoring of vital signs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of need for allogenic blood transfusion. Timepoint: During and immediately after the surgery. Method of measurement: Number of received pack cell units. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarhang Rashidi
Tehran University of Medical Sciences
Outcome results
None listed